I agree. When I first posted the French paper on HC I didn't expect RAC to go after T2D with their own pre-clinical. My thinking is that anything beyond cancer will be outside RAC's circle of competence and too much of a distraction to pursue outright...
HOWEVER that doesn't eliminate the possibility of minor adaptions to existing programs. Any chances here @RaceOncology?
Ann: Quarterly Activity Report & Appendix 4C, page-26
-
- There are more pages in this discussion • 51 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.70 |
Change
0.090(5.59%) |
Mkt cap ! $289.5M | |||
| Open | High | Low | Value | Volume |
| $1.60 | $1.76 | $1.59 | $142.7K | 84.97K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 17175 | $1.70 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.77 | 6060 | 1 |
View Market Depth
| Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |